This paper is only available as a PDF. To read, Please Download here.
ABSTRACT
Background and aims
The single dose of 2L polyethylene glycol (PEG) has shown high cleaning efficacy and tolerability in low-risk patients. However, the dosage of this regimen is still challenging for many patients. We investigated the efficacy and tolerability of a novel ultra-volume regimen using 1L PEG and linaclotide (1L PEG+L) versus single dose of 2L PEG in low-risk patients.
Methods
In this prospective, randomized, observer-blinded, multicenter study, low-risk adult patients scheduled for colonoscopy were enrolled and randomized (1:1) to receive 1L PEG+L or 2L PEG regimen. The primary outcome was the effectiveness of bowel cleansing according to the Boston Bowel Preparation Scale (BBPS). Secondary outcomes included cecal intubation rate, cecal insertion time, withdrawal time, polyp detection rate (PDR) and adenoma detection rate (ADR), tolerability, adverse events, and willingness to repeat bowel preparation. The full analysis set (FAS) and per-protocol set (PPS) were used for statistical analyses.
Results
A total of 548 patients comprised the FAS while 522 patients comprised the PPS. Non-inferiority on adequate bowel cleansing of 1L PEG+L vs 2L PEG was established both in FAS (90.5% vs 91.6%, P =0.644) and PPS (90.3% vs 92.4%, P =0.390). There were no significant differences with regard to the total and each segment scores of BBPS, cecal intubation rate, cecal insertion time, withdrawal time, PDR and ADR (all P > 0.05). However, patients in 1L PEG+L group reported less nausea (7.7% vs 17.1%, P <0.01), vomiting (4.0% vs 10.9%, P <0.01) and had a higher willingness to repeat (95.2% vs 82.2%, P <0.01).
Conclusions
1L PEG+L regimen was not inferior to 2L PEG on colon cleansing with better tolerability and higher willingness to repeat in low-risk population.
Graphical abstract
Graphical Abstract
Key words
Article info
Publication history
Accepted:
December 14,
2022
Received in revised form:
November 22,
2022
Received:
September 20,
2022
Publication stage
In Press Journal Pre-ProofFootnotes
CZ, XC and BT contributed equally to this work.
Identification
Copyright
© 2022 by the American Society for Gastrointestinal Endoscopy
User license
Creative Commons Attribution – NonCommercial – NoDerivs (CC BY-NC-ND 4.0) | How you can reuse 
Elsevier's open access license policy
Creative Commons Attribution – NonCommercial – NoDerivs (CC BY-NC-ND 4.0)
Permitted
For non-commercial purposes:
- Read, print & download
- Redistribute or republish the final article
- Text & data mine
- Translate the article (private use only, not for distribution)
- Reuse portions or extracts from the article in other works
Not Permitted
- Sell or re-use for commercial purposes
- Distribute translations or adaptations of the article
Elsevier's open access license policy
02225-8&id=fx1.jpg){kind=link}